Physician profile
Angela Luongo
NPI 1093991911
$11,150.46
in general payments reported to CMS, 2019-2025
66 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,730 · 2022: $2,145 · 2023: $2,261 · 2024: $2,315 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,568 · Consulting Fee: $475 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $8.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,567.89 |
| Consulting Fee | $475.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $8.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,084.33 | 2021-2025 | |
| Daiichi Sankyo INC. | $918.97 | 2021-2025 | Injectafer, Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $678.58 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Glaxosmithkline, LLC. | $521.77 | 2022-2025 | Ojjaara, Jemperli, Shingrix |
| Pfizer INC. | $501.04 | 2022-2025 | |
| Genzyme Corporation | $495.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $480.20 | 2021-2025 | Opdivo, Krazati, Augtyro |
| Genentech USA, INC. | $471.53 | 2021-2025 | Polivy, Venclexta, Lunsumio |
| Celgene Corporation | $370.00 | 2021-2025 | Reblozyl |
| Amgen INC. | $347.73 | 2021-2025 | Prolia, Lumakras, Nplate |
| Merck Sharp & Dohme LLC | $263.15 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astellas Pharma US INC | $259.07 | 2021-2025 | Xtandi, Padcev, Vyloy |
| Abbvie INC. | $234.50 | 2023-2025 | |
| Coherus Oncology, INC. | $233.31 | 2021-2024 | |
| Eisai INC. | $221.31 | 2021-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $220.37 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Lilly USA, LLC | $214.94 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Beigene USA, INC. | $208.96 | 2021-2024 | Brukinsa |
| Seagen INC. | $190.22 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $186.84 | 2021-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Incyte Corporation | $183.83 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Rigel Pharmaceuticals, INC. | $172.26 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sobi, INC | $169.31 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.35 | 2021-2025 | |
| Kite Pharma, INC. | $143.89 | 2021-2024 | Yescarta |
| Pharmacosmos Therapeutics INC. | $139.93 | 2021-2025 | Monoferric |
| Array Biopharma INC | $137.81 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $102.27 | 2023-2025 | Libtayo |
| Kyowa Kirin, INC. | $99.92 | 2021-2025 | Poteligeo |
| Ipsen Biopharmaceuticals, INC | $94.21 | 2021-2024 | Onivyde |
| Exelixis INC. | $84.88 | 2023-2025 | Cabometyx |
| Organon LLC | $82.44 | 2021-2023 | Ontruzant |
| Stemline Therapeutics INC. | $79.87 | 2023-2025 | Orserdu, Elzonris |
| Jazz Pharmaceuticals INC. | $79.04 | 2021-2023 | |
| Emd Serono, INC. | $79.03 | 2021-2025 | Bavencio |
| Shield Therapeutics INC | $75.64 | 2023-2024 | Accrufer |
| Genmab U.S., INC. | $74.79 | 2024-2025 | Epkinly, Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $73.54 | 2021-2023 | Imbruvica |
| Puma Biotechnology, INC. | $71.54 | 2024-2025 | |
| Pharmaessentia USA Corporation | $67.95 | 2022-2025 | Besremi |
| Mirati Therapeutics, INC. | $60.88 | 2023-2024 | Krazati |
| Gilead Sciences, INC. | $58.84 | 2022-2025 | Trodelvy |
| Taiho Oncology, INC. | $57.80 | 2021-2025 | |
| Celltrion USA INC. | $57.53 | 2024-2025 | Vegzelma |
| Karyopharm Therapeutics INC. | $55.85 | 2021-2023 | Xpovio |
| Geron Corporation | $55.73 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $51.69 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $50.07 | 2022 | |
| Servier Pharmaceuticals LLC | $42.10 | 2021-2023 | |
| Mylan Institutional INC. | $36.63 | 2022-2023 | Fulphila, Ogivri |
| Alexion Pharmaceuticals, INC. | $34.79 | 2021-2023 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $33.31 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $32.52 | 2024-2025 | Orgovyx |
| Immunogen, INC. | $31.06 | 2023-2024 | Elahere, Elahere |
| Fresenius Kabi USA, LLC | $30.56 | 2022 | |
| G1 Therapeutics, INC. | $24.84 | 2023 | Cosela |
| Tg Therapeutics, INC. | $23.12 | 2022 | |
| Tersera Therapeutics LLC | $20.98 | 2025 | Zoladex |
| Apellis Pharmaceuticals, INC. | $18.02 | 2023 | Empaveli |
| Deciphera Pharmaceuticals INC. | $15.14 | 2023 | Qinlock |
| Dova Pharmaceuticals | $14.95 | 2021 | |
| Cti Biopharma Corp. | $14.85 | 2023 | Vonjo |
| Amneal Pharmaceuticals LLC | $14.52 | 2025 | Alymsys |
| Progenics Pharmaceuticals, INC. | $14.15 | 2023 | Pylarify |
| Heron Therapeutics, INC. | $12.88 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Luongo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.